Taste Masking
Developing novel pharmaceutical technology that provides for outstanding taste masking for a broad range of pharmaceuticals including major drug categories such as NSAIDS and statins.
Technologies
OXP target™ utilises a novel drug delivery technology that provides superior controlled delivery of drugs to the distal ileum, proximal colon and colon using dual pH and bacterial trigger systems. Initially it is being used to target the delivery of statins to the colon.
The targeting of statins to the colon allows the development of reformulations of a range of statins such as simvastatin, losuvastatin and atorvastatin that are bioequivalent with currently available formulations at significantly reduced dosage levels, thus reducing the risk of side-effects and of negative drug-drug interactions.
The colonic drug-delivery system which underpins OXP target™ is licensed from The School of Pharmacy, University of London. This system ("Phloral") is being applied to statins to develop products that not only have lower risk of side effects or negative interactions but also offer favourable pharmaco economics. The Phloral™ technology is the subject of wordwide patent applications belonging to the School of Pharmacy, stemming from a UK application filed in 2006.
The company is making the technology available to partners under a sub-licensing agreement to co-develop applications for Statins.